IRAK-M Activators
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amlexanox | 68302-57-8 | sc-217630 | 10 mg | $160.00 | 2 | |
Amlexanox inhibits IKKε/TBK1, suppressing the TLR signaling pathway. This inhibition indirectly activates IRAK-M by preventing its degradation, allowing IRAK-M to exert its anti-inflammatory effects through the inhibition of IRAK-1 and TRAF6, key components in TLR-mediated inflammation. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
TPCA-1 (IKK-2 Inhibitor IV) is a selective inhibitor of IKK-2, a crucial kinase in the NF-κB pathway. Inhibition of IKK-2 indirectly activates IRAK-M by preventing NF-κB-mediated inflammation, allowing IRAK-M to exert its anti-inflammatory effects by inhibiting IRAK-1 and TRAF6, key players in the TLR signaling pathway. | ||||||
BAY 11-7085 | 196309-76-9 | sc-202490 sc-202490A | 10 mg 50 mg | $124.00 $526.00 | 55 | |
Bay 11-7085 inhibits IKKβ, a component of the IKK complex in the NF-κB pathway. Inhibition of IKKβ indirectly activates IRAK-M by disrupting NF-κB-mediated inflammation, enabling IRAK-M to inhibit IRAK-1 and TRAF6, key regulators in the TLR signaling cascade, ultimately suppressing inflammatory responses. | ||||||
A77 1726 | 163451-81-8 | sc-207235 | 10 mg | $80.00 | 14 | |
A77 1726, an active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase, impacting pyrimidine synthesis. This disruption indirectly activates IRAK-M by modulating cellular metabolism, leading to the inhibition of IRAK-1 and TRAF6, key components in the TLR signaling pathway, thereby attenuating inflammatory responses. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
Parthenolide inhibits the NF-κB pathway by preventing IκBα phosphorylation. This inhibition indirectly activates IRAK-M by disrupting NF-κB-mediated inflammation, allowing IRAK-M to inhibit IRAK-1 and TRAF6, crucial players in the TLR signaling cascade, leading to the suppression of inflammatory responses. | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | $158.00 | 6 | |
Celastrol inhibits the NF-κB pathway by suppressing IKK activity. Inhibition of IKK indirectly activates IRAK-M by preventing NF-κB-mediated inflammation, enabling IRAK-M to inhibit IRAK-1 and TRAF6, key components in the TLR signaling pathway, ultimately suppressing inflammatory responses. | ||||||
CDDO Imidazolide | 443104-02-7 | sc-504719 | 1 mg | $700.00 | ||
CDDO Imidazolide activates Nrf2, promoting antioxidant responses. This activation indirectly activates IRAK-M by enhancing cellular antioxidant defenses, allowing IRAK-M to inhibit IRAK-1 and TRAF6, crucial players in the TLR signaling pathway, ultimately suppressing inflammatory responses. | ||||||
SC514 | 354812-17-2 | sc-205504 sc-205504A | 5 mg 10 mg | $67.00 $91.00 | 13 | |
SC514 inhibits IKK-2, a key kinase in the NF-κB pathway. Inhibition of IKK-2 indirectly activates IRAK-M by disrupting NF-κB-mediated inflammation, allowing IRAK-M to inhibit IRAK-1 and TRAF6, key components in the TLR signaling cascade, ultimately suppressing inflammatory responses. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A inhibits NF-κB activity by preventing IκBα phosphorylation. Inhibition of NF-κB indirectly activates IRAK-M by disrupting NF-κB-mediated inflammation, enabling IRAK-M to inhibit IRAK-1 and TRAF6, key players in the TLR signaling pathway, ultimately suppressing inflammatory responses. | ||||||
Andrographolide | 5508-58-7 | sc-205594 sc-205594A | 50 mg 100 mg | $15.00 $40.00 | 7 | |
Andrographolide inhibits NF-κB activation by preventing IκBα phosphorylation. Inhibition of NF-κB indirectly activates IRAK-M by disrupting NF-κB-mediated inflammation, allowing IRAK-M to inhibit IRAK-1 and TRAF6, key components in the TLR signaling cascade, leading to the suppression of inflammatory responses. | ||||||